What does a pilot study say about deep longitudinal profiling for metastatic cancer patients?

You asked about a pilot study on deep longitudinal profiling for metastatic cancer patients. Deep longitudinal profiling involves repeatedly collecting and analyzing biological samples (like blood or tumor tissue) over time to track how a cancer evolves and responds to treatment. However, none of the provided sources discuss this topic. The sources cover dermoscopy for skin cancer, inflammaging in colorectal cancer, omega-3 fatty acids for pancreatic cancer, natural products in preclinical models, acupuncture for neuropathy, immune checkpoint inhibitors for cervical cancer, microbiome in breast cancer, and breast cancer metastasis to the thyroid. None address deep longitudinal profiling or pilot studies in metastatic cancer.

What the research says

The available sources do not provide any information on deep longitudinal profiling for metastatic cancer patients. The closest related topics are studies on cancer biomarkers and treatment monitoring, but none specifically describe a pilot study using deep longitudinal profiling. For example, one review discusses inflammaging and immunosenescence in colorectal cancer ², and another reviews host-microbiome interactions in breast cancer ⁷, but neither involves longitudinal profiling. A meta-analysis on immune checkpoint inhibitors in cervical cancer reports survival outcomes ⁶, but does not use deep profiling. Therefore, based on the provided sources, there is no evidence to answer your question.

What to ask your doctor

• Are there any ongoing clinical trials at this center that use deep longitudinal profiling for metastatic cancer?
• What are the potential benefits and limitations of deep longitudinal profiling for monitoring my cancer?
• How might deep profiling help guide treatment decisions compared to standard imaging or blood tests?
• Is there published research on deep profiling for my specific type of metastatic cancer?